Details
Stereochemistry | RACEMIC |
Molecular Formula | C24H26FN3O |
Molecular Weight | 391.4811 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=C(C=C1)C(=O)CCCN2CCN3CC4=C(CC3C2)C5=CC=CC=C5N4
InChI
InChIKey=YCNCIZWAGQTWBI-UHFFFAOYSA-N
InChI=1S/C24H26FN3O/c25-18-9-7-17(8-10-18)24(29)6-3-11-27-12-13-28-16-23-21(14-19(28)15-27)20-4-1-2-5-22(20)26-23/h1-2,4-5,7-10,19,26H,3,6,11-16H2
Molecular Formula | C24H26FN3O |
Molecular Weight | 391.4811 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Biriperone (also known as Centbutindole) was developed as an antipsychotic drug. It has shown effective antipsychotic activity in schizophrenic patients. Biriperone acts as a dopamine antagonist, and also as a blocker of 5HT(2) receptor. Clinically the drug has passed through phase I, II & III clinical trials successfully, however, the use of this drug was banned.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL339 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17869521 |
7.88 null [pKi] | ||
Target ID: CHEMBL322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17869521 |
7.619 null [pKi] |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of dopamine agonists and antagonists on the lorazepam withdrawal syndrome in rats. | 2000 Mar |
|
Metabolism and excretion of centbutindole (neuroleptic) in rats after oral administration. | 2002 Dec |
|
Comparative efficacy of centbutindole & risperidone in schizophrenia. | 2002 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21206602
Patietns were randomly allocated to receive either 4.5mg of centbutindole
or 6 mg of risperidone. The drug was formulated in capsules identical in colour, shape and size. Each capsule contained centbutidole (1.5 mg) or risperidone (2 mg). Initial dose was 1 Capsule twice a day for three days increasing to 1 capsule in the morning and 2 capsule at bed time through out the study period of 8 weeks.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:21:14 GMT 2023
by
admin
on
Fri Dec 15 16:21:14 GMT 2023
|
Record UNII |
5776HBV7UD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5472
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
143691
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
68663
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL136711
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
3883
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
C76438
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
5776HBV7UD
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
SUB05845MIG
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
DTXSID60866048
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
41510-23-0
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY | |||
|
100000085910
Created by
admin on Fri Dec 15 16:21:14 GMT 2023 , Edited by admin on Fri Dec 15 16:21:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |